The Food and Drug Administration is walking back President Trump's statement that the agency has approved theanti-malarial drug chloroquineas a treatment modality for COVID-19.

No drug has yet been approved to fight the disease caused by the novel coronavirus. But some physicians and hospitals have been using the drug off-label, and manufacturers say they'll soon be experiencing shortages.

The University of Minnesota isconducting a studyto see whether chloroquine can protect people who have coronavirus exposure. Host Robin Young talks toDr. Len Horovitz, a pulmonologist at Lenox Hill Hospital in New York.